INKT

INKT

Mink Therapeutics Inc

Net -15.85%top 1%Rev โ€”top 1%1Y
Hold

MiNK Therapeutics specializes in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its pipeline includes therapies targeting various cancers and viral respiratory distress, focusing on off-the-shelf solutions.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$800today

Score Overview

1 Year
Scoreโ€”
Net Growth-15.85%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth58.65%
Net Trend75%
Net Income Consistency
Rev Growthโ€”
Rev Trend25%
Revenue Consistency

See the full market ranking โ†’

Mink Therapeutics Inc fundamental performance

Across Mink Therapeutics Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 30M to -$ 12M. Revenue increased in 25% of the years measured; net income in 75%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 11.36โ€”
1 Year2025-08-12
$ 14.20-20.00%
All Time2021-10-15
$ 120.00-90.53%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 0.00-$ 12M$ 13.36B
2024$ 0.00-$ 10M$ 4M
2023$ 0.00-$ 22M$ 3M
2022$ 2.70B-$ 27M$ 19M
IPO2021$ 0.00-$ 30M$ 38M

Explore beyond INKT

You're looking at Mink Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies